PharmTech Drug Digest 11.20
News|Articles|October 22, 2009

Regulatory Roundup: FDA and FTC Issue Joint Warning Letter on H1N1 Products

The two agencies issued a joint Warning Letter to the owners of a website selling unapproved products intended to treat the swine flu virus.

The US Food and Drug Administration and Federal Trade Commission issued a joint Warning Letter on Oct. 19, 2009, to a website offering fraudulent supplements that claim to help prevent the spread of the swine-flu virus, according to an FDA release. The website was asked to cease the fraudulent marketing and advise the agencies of its plan to discontinue fraudulent marketing within 48 hours of receiving the letter. FDA and FTC also asked consumers to be cautious of “promotions or Internet sites offering products for sale that claim to diagnose, prevent, mitigate, treat or cure the 2009 H1N1 influenza virus.”


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.